DCM
CRNX icon

Driehaus Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Driehaus Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242M Buy
6,463,551
+67,629
+1% +$2.51M 1.4% 7
2026
Q1 		$232M Buy
6,395,922
+8,182
+0.1% +$365K 1.71% 4
2025
Q4 		$297M Sell
6,387,740
-93,873
-1% -$4.18M 2.02% 2
2025
Q3 		$270M Buy
6,481,613
+81,588
+1% +$2.61M 1.93% 2
2025
Q2 		$184M Buy
6,400,025
+160,123
+3% +$4.94M 1.47% 6
2025
Q1 		$209M Buy
6,239,902
+98,888
+2% +$3.69M 2.02% 3
2024
Q4 		$314M Buy
6,141,014
+255,766
+4% +$14.3M 2.59% 2
2024
Q3 		$301M Sell
5,885,248
-226,925
-4% -$11.7M 2.58% 2
2024
Q2 		$274M Buy
6,112,173
+885,876
+17% +$40.9M 2.65% 2
2024
Q1 		$245M Buy
5,226,297
+186,340
+4% +$7.29M 2.44% 3
2023
Q4 		$179M Sell
5,039,957
-92,330
-2% -$2.83M 2.16% 3
2023
Q3 		$153M Sell
5,132,287
-165,801
-3% -$3.42M 1.98% 4
2023
Q2 		$95.5M Buy
5,298,088
+8,569
+0.2% +$171K 1.21% 11
2023
Q1 		$84.9M Sell
5,289,519
-335,225
-6% -$6.2M 1.19% 7
2022
Q4 		$103M Sell
5,624,744
-7,214
-0.1% -$127K 1.53% 5
2022
Q3 		$111M Buy
5,631,958
+157,499
+3% +$3.21M 1.67% 4
2022
Q2 		$102M Buy
5,474,459
+530,446
+11% +$10.6M 1.65% 4
2022
Q1 		$109M Buy
4,944,013
+150,375
+3% +$3.04M 1.33% 5
2021
Q4 		$136M Buy
4,793,638
+1,795,126
+60% +$44.3M 1.39% 4
2021
Q3 		$63.1M Buy
2,998,512
+290,687
+11% +$6.08M 0.75% 32
2021
Q2 		$51M Buy
2,707,825
+704,137
+35% +$12.4M 0.68% 31
2021
Q1 		$30.6M Buy
2,003,688
+549,722
+38% +$8.52M 0.45% 59
2020
Q4 		$20.5M Buy
1,453,966
+579,124
+66% +$8.07M 0.33% 96
2020
Q3 		$13.7M Sell
874,842
-11,920
-1% -$182K 0.28% 102
2020
Q2 		$15.5M Buy
+886,762
New +$15.1M 0.38% 79

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Driehaus Capital Management's CRNX Position: Q2 2026 in Review

Driehaus Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 1.1% in Q2 2026, buying an estimated $2.51M and bringing the position to 6,463,551 shares worth $242M. The position accounts for 1.4% of the portfolio, ranked #7.

Driehaus Capital Management first reported a position in CRNX in Q2 2020 and has held it in 25 quarters since. The position peaked at $314M in Q4 2024. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Driehaus Capital Management held 6,463,551 shares of Crinetics Pharmaceuticals worth $242M as of Q2 2026.
  • Driehaus Capital Management bought 67,629 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.51M.
  • Crinetics Pharmaceuticals made up 1.4% of Driehaus Capital Management's portfolio in Q2 2026, its #7 holding.
  • Driehaus Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Driehaus Capital Management's Crinetics Pharmaceuticals position peaked at $314M in Q4 2024.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.